# US 2024/0200148 A1 · Analysis of effluent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200148 A1
- Document ID: US20240200148A1
- Status: Published application
- Kind: A1
- Application number: 18/542,057
- Filed: 2023-12-15
- Published: 2024-06-20
- Earliest claimed: 2022-12-16
- Assignees: Droplet Biosciences, Inc.
- Applicants: Droplet Biosciences, Inc.
- Inventors: Wendy Winckler Adamovich
- Web page: https://patentgrep.com/patent/US20240200148A1

## CPC

- C12Q 1/6851: Quantitative amplification
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/689: for bacteria
- G01N 33/56911: {Bacteria}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/6869: {Interleukin}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/54: Interleukins [IL]
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods of detecting, or predicting the aggressiveness of, a tumor by measuring cancer biomarkers in surgical drain fluid that may be collected from the site of a surgery such as a tumor resection or lymphadenectomy. Surgical drain fluid (SDF), and the lymph component of SDF in particular, contains biomarkers that demonstrably correlate to future cancer outcomes and that are thus predictive of the growth or aggressiveness of a tumor.

## Claims

### Claim 1

A method of predicting cancer recurrence, the method comprising:
obtaining lymphatic fluid from a site proximal to a tumor;
measuring a level of a predetermined protein in the lymphatic fluid; and
predicting recurrence of the cancer on the basis of the measured level.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protein is an inflammatory protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the protein is a cytokine.

### Claim 4 (depends on 1)

The method of claim 1, wherein the protein is an interleukin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the protein is IL-1beta.

### Claim 6 (depends on 1)

The method of claim 1, wherein the site is a surgical site of removal of the tumor.

### Claim 7 (depends on 6)

The method of claim 6, wherein the lymphatic fluid is obtained as drain fluid that drains from the surgical site and is obtained during and after surgical removal of the tumor, and method comprises making a first measurement in fluid obtained during the removal and a second measurement in fluid obtained after the surgical removal of the tumor.

### Claim 8 (depends on 1)

The method of claim 1, further comprising measuring levels of a plurality of proteins in the lymphatic fluid.

### Claim 9 (depends on 8)

The method of claim 8, wherein the proteins include cytokines.

### Claim 10 (depends on 1)

The method of claim 1, wherein the measuring step further includes sequencing circulating tumor DNA (ctDNA) from the lymphatic fluid to identify a number of tumor mutations in the ctDNA.

### Claim 11 (depends on 10)

The method of claim 10, further comprising deriving a tumor mutational burden (TMB) from the number of tumor mutations, wherein a high TMB is predictive of recurrence.

### Claim 12 (depends on 1)

The method of claim 1, wherein the measuring step includes performing an assay to quantify the level of the protein the lymphatic fluid, wherein the assay includes binding labeled antibodies to the proteins.

### Claim 13 (depends on 1)

The method of claim 1, wherein the protein is IL-1β and the method include predicting recurrence of the tumor when the IL-1β is present at a concentration of at least 30 pg/mL in the lymphatic fluid.

### Claim 14

A method of therapeutic selection, the method comprising:
obtaining lymphatic fluid from a site proximal to a tumor in a subject;
measuring a level of a predetermined protein in the lymphatic fluid; and
selecting a treatment for the subject on the basis of the measured level.

### Claim 15 (depends on 14)

The method of claim 14, wherein the lymphatic fluid is obtained after surgery to remove the tumor, and the treatment is selected for adjuvant therapy.

### Claim 16

The method of 14, wherein the protein is a pro-inflammatory cytokine, and the measured level is used to select an adjuvant therapy.

### Claim 17 (depends on 14)

The method of claim 14, wherein the selected treatment comprises an antibody.

### Claim 18 (depends on 14)

The method of claim 14, wherein the selected treatment comprises an interleukin inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the interleukin inhibitor comprises the IL-1beta inhibitor anakinra, canakinumab, or rilonacept.

### Claim 20 (depends on 18)

The method of claim 18, wherein the selected treatment comprises the interleukin inhibitor in combination with a treatment comprising chemotherapy, radiation, or an immunotherapy.

### Claim 21 (depends on 14)

The method of claim 14, wherein the protein is IL-1β and the selected treatment comprises an IL-1β inhibitor.

### Claim 22

A method of predicting a cancer therapy outcome, the method comprising:
obtaining lymphatic fluid from a site proximal to a tumor in a subject who has been treated for cancer by a neoadjuvant therapy and surgery;
measuring a level of a predetermined protein in the lymphatic fluid; and
determining a pharmacodynamic effect of the neoadjuvant therapy on the basis of the measured level.

### Claim 23 (depends on 22)

The method of claim 22, wherein the protein is a cytokine or an interleukin.

### Claim 24 (depends on 23)

The method of claim 23, wherein the protein is IL-1β.

### Claim 25 (depends on 22)

The method of claim 22, wherein the neoadjuvant therapy comprises an IL-1β inhibitor.

### Claim 26 (depends on 22)

The method of claim 22, wherein the neoadjuvant therapy comprises an IL-1β inhibitor in combination with a treatment comprising chemotherapy, radiation, or an immunotherapy.
